Efficacy and safety of sclerotherapy with polidocanol in children with internal hemorrhoids

Pediatr Int. 2021 Jul;63(7):813-817. doi: 10.1111/ped.14506. Epub 2021 May 26.

Abstract

Background: Hemorrhoids are an extremely rare condition in children, and data on its incidence and treatment in the pediatric population remains scarce. We retrospectively reviewed children who underwent sclerotherapy for internal hemorrhoids, and analyzed patients' characteristics and outcomes.

Methods: A total of 14 pediatric patients who underwent sclerotherapy were included. Patients' ages and the required amount of polidocanol, depending on the grade of hemorrhoids, and the correlation between age and volume of sclerosant, were statistically analyzed.

Results: Patients had a male predominance with a ratio of 2.5:1 (grade 2:6 patients, grade 3:8 patients). Four children had underlying conditions including portal hypertension and Klippel-Trenaunay syndrome. Of the 14 patients, 43% had constipation requiring medication or enema. Only one minor complication, a perianal ulceration, was found to be associated with sclerotherapy. Patients with grade 3 hemorrhoids required a significantly larger amount of polidocanol than those with grade 2 hemorrhoids. Two patients with grade 3 hemorrhoids required a second session of treatment for recurrence. The success rate of sclerotherapy with polidocanol was 86%.

Conclusions: Sclerotherapy with polidocanol is a safe, effective, and less invasive treatment option for internal hemorrhoids in children. Further studies are needed to investigate this treatment approach.

Keywords: child; hemorrhoid; polidocanol; sclerotherapy.

MeSH terms

  • Child
  • Hemorrhoids* / drug therapy
  • Humans
  • Male
  • Polidocanol
  • Polyethylene Glycols / adverse effects
  • Retrospective Studies
  • Sclerosing Solutions / therapeutic use
  • Sclerotherapy* / adverse effects
  • Treatment Outcome

Substances

  • Sclerosing Solutions
  • Polidocanol
  • Polyethylene Glycols